CRO Quality Benchmarking - Phase I Service Providers -





CRO Quality Benchmarking Phase I Service Providers (6th edition) 

In its 6th year, ISR’s “CRO Quality Benchmarking Phase I Service Providers” report provides pharmaceutical sponsors and service providers a Consumer Reports-style analysis of CRO quality. Respondents supplied satisfaction ratings from 414 service encounters across 27 Phase I CROs, making this report the most comprehensive assessment of Phase I CRO service quality in the industry.

 
  • 414 Service Encounters
  • 113 Respondents
  • 247 Charts and Graphs
 

How you can use this report:

Study Sponsors 

  • Make a more informed purchase of Phase I services by understanding which service providers best fit your company’s needs
  • Broaden your Phase I CRO evaluation list by accessing peer-based service quality ratings across 27 critical attributes
  • Pinpoint potential delivery concerns early in a CRO relationship/ evaluation in order to develop proactive strategies to address potential gaps

Phase I Service Providers 

  • Uncover your own — and competitor — delivery strengths and weaknesses
  • Design messaging to tout your company’s strengths
  • Compete more effectively by understanding buyers’ selection criteria and outsourcing trends

 

Report Structure:

1. Outsourcing Behaviors, Attitudes, Beliefs, and Intentions 

  • Phase I Leaders
  • Proposal Volume
  • Service Provider Usage
  • Service Provider Preference
  • Service Provider Cost Perceptions

2. Service Provider Selection Drivers 

  • Most Important Service Provider Attributes
  • Service Provider Attributes Gaining Importance

3. Service Provider Performance and Scorecards Across Attributes 

  • “Staff Characteristics” Ratings
  • “Operational Excellence” Ratings
  • “Organizational and Finance” Ratings
  • Performance Summary by Category
  • Service Provider Loyalty

4. Service Provider Service Quality Profiles 

5. All Study Data 

 

CROs Included in this Report

 

  • Biotrial
  • CEDRA
  • Celerion
  • CHDR
  • Chiltern
  • Clinical Research Services (CRS)
  • Covance
  • DaVita
  • DCRI-Duke
  • Frontage
  • HungaroTrial
  • ICON
  • INC Research
  • inVentiv Health Clinical
  • Medpace
  • PAREXEL
  • PPD
  • PRA
  • Premier Research
  • Quintiles
  • Quotient Clinical
  • Rho
  • SGS Life Sciences
  • Siro Clinpharm
  • Theorem
  • US Oncology
  • WCCT Global
 

 

Table of Contents
 
Copyright and Usage Guidelines ..................................................................................................................6
Introduction .................................................................................................................................................7
Methodology ...............................................................................................................................................8
Respondent Demographics and Qualifications ............................................................................................9
Participant Years of Industry Experience .............................................................................................9
Participant Geography .........................................................................................................................9
Participant Company Size ....................................................................................................................9
Number of Ratings per Company ...............................................................................................................10
Major Sections ...........................................................................................................................................11
Outsourcing Behaviors, Attitudes, Beliefs, and Intentions ........................................................................12
Phase I Leaders, Unprompted ............................................................................................................13
Phase I Leaders, Prompted .................................................................................................................14
Proposal Volume ................................................................................................................................15
Service Provider Usage .......................................................................................................................16
Service Provider Preference ...............................................................................................................17
Service Provider Cost Experience .......................................................................................................18
Summary Table ..................................................................................................................................19
Service Provider Selection Drivers .............................................................................................................20
Most Important Service Provider Attributes ......................................................................................21
Service Provider Attributes Gaining Importance ...............................................................................23
Service Provider Performance and Scorecards Across Attributes .............................................................24
Figure 1 – “Staff Characteristics” Ratings ..........................................................................................26
Figure 2 – “Operational Excellence” Ratings .....................................................................................27
Figure 3 – “Organizational and Finance” Ratings …….........................................................................28
Performance Summary by Category ..................................................................................................29
Service Provider Loyalty .....................................................................................................................30
Company Service Quality Profiles ..............................................................................................................32
Celerion ..............................................................................................................................................34
Clinical Research Services (CRS) .........................................................................................................35
Covance ..............................................................................................................................................36
ICON ...................................................................................................................................................37
INC Research ......................................................................................................................................38
inVentiv Health Clinical ......................................................................................................................39
Medpace ............................................................................................................................................40
PAREXEL .............................................................................................................................................41
PPD .....................................................................................................................................................42
PRA .....................................................................................................................................................43
Premier Research ...............................................................................................................................44
Quintiles .............................................................................................................................................45
Quotient Clinical .................................................................................................................................46
SGS Life Sciences ................................................................................................................................47
US Oncology .......................................................................................................................................48
WCCT Global ......................................................................................................................................49
Phase I Study Data .....................................................................................................................................50
Phase I Leaders, Unprompted ............................................................................................................51
Phase I Leaders, Prompted .................................................................................................................53
Proposal Volume ................................................................................................................................54
Most Important Service Provider Attributes .....................................................................................55
Service Provider Attributes Gaining Importance ...............................................................................56
Service Provider Usage .......................................................................................................................57
Service Provider Preference ...............................................................................................................58
Best Service Provider at Differentiation .............................................................................................59
Service Provider Cost Experience .......................................................................................................60
Service Provider Cost Experience Among Users in Past 18 Months ...................................................61
Service Provider Cost Experience Among Lapsed Users and Non-users ............................................62
Service Provider Cost Perceptions .....................................................................................................63
Service Provider Budget Allocation ....................................................................................................64
Outsourcing Volume Past 12 months .................................................................................................65
Outsourcing Volume Next 12 months ................................................................................................66
Service Provider Loyalty .........................................................................................................................67
Service Provider Loyalty .....................................................................................................................67
Service Provider Loyalty – Past 3 Years ..............................................................................................68
Service Provider Loyalty – Rolling Average ........................................................................................69
Service Provider Loyalty - Company Size ...........................................................................................70
Overall Satisfaction with Service Providers .......................................................................................71
Willingness to Recommend Service Providers ...................................................................................72
Likelihood to Use Service Providers Again .........................................................................................73
Service Provider Drill-downs ..................................................................................................................74
Biotrial Use and Satisfaction ..............................................................................................................74
Biotrial Performance Against Expectations ........................................................................................75
CEDRA Use and Satisfaction ...............................................................................................................76
CEDRA Performance Against Expectations ........................................................................................77
Celerion Use and Satisfaction ............................................................................................................78
Celerion Performance Against Expectations ......................................................................................79
CHDR Use and Satisfaction ................................................................................................................80
CHDR Performance Against Expectations ..........................................................................................81
Chiltern Use and Satisfaction .............................................................................................................82
Chiltern Performance Against Expectations .......................................................................................83
Clinical Research Services (CRS) Use and Satisfaction ........................................................................84
Clinical Research Services (CRS) Performance Against Expectations .................................................85
Covance Use and Satisfaction ............................................................................................................86
Covance Performance Against Expectations .....................................................................................87
DaVita Use and Satisfaction ...............................................................................................................88
DaVita Performance Against Expectations ........................................................................................89
DCRI-Duke Use and Satisfaction ........................................................................................................90
DCRI-Duke Performance Against Expectations .................................................................................91
Frontage Use and Satisfaction ..........................................................................................................92
Frontage Performance Against Expectations ....................................................................................93
HungaroTrial Use and Satisfaction ....................................................................................................94
HungaroTrial Performance Against Expectations ..............................................................................95
ICON Use and Satisfaction .................................................................................................................96
ICON Performance Against Expectations ..........................................................................................97
INC Research Use and Satisfaction ....................................................................................................98
INC Research Performance Against Expectations ..............................................................................99
inVentiv Health Clinical Use and Satisfaction ..................................................................................100
inVentiv Health Clinical Performance Against Expectations ............................................................101
Medpace Use and Satisfaction .........................................................................................................102
Medpace Performance Against Expectations ..................................................................................103
PAREXEL Use and Satisfaction ..........................................................................................................104
PAREXEL Performance Against Expectations ...................................................................................105
PPD Use and Satisfaction .................................................................................................................106
PPD Performance Against Expectations ..........................................................................................107
PRA Use and Satisfaction .................................................................................................................108
PRA Performance Against Expectations ..........................................................................................109
Premier Research Use and Satisfaction ...........................................................................................110
Premier Research Performance Against Expectations .....................................................................111
Quintiles Use and Satisfaction .........................................................................................................112
Quintiles Performance Against Expectations ...................................................................................113
Quotient Clinical Use and Satisfaction .............................................................................................114
Quotient Clinical Performance Against Expectations ......................................................................115
Rho Use and Satisfaction .................................................................................................................116
Rho Performance Against Expectations ...........................................................................................117
SGS Life Sciences Use and Satisfaction ...........................................................................................118
SGS Life Sciences Performance Against Expectations .....................................................................119
Siro Clinpharm Use and Satisfaction ...............................................................................................120
Siro Clinpharm Performance Against Expectations .........................................................................121
Theorem Use and Satisfaction .........................................................................................................122
Theorem Performance Against Expectations ..................................................................................123
US Oncology Use and Satisfaction ..................................................................................................124
US Oncology Performance Against Expectations ............................................................................125
WCCT Global Use and Satisfaction ...................................................................................................126
WCCT Global Performance Against Expectations ............................................................................127
Cross-service provider performance ....................................................................................................128
Access to “unique” tests, machines, equipment .............................................................................128
Access to a broad range of services .................................................................................................129
Access to patient populations ..........................................................................................................129
Data quality ......................................................................................................................................130
Experience of the Phase I unit’s lead investigator ...........................................................................130
Financial strength / stability ............................................................................................................131
Local market / Regulatory knowledge .............................................................................................131
Location of Phase I unit(s) in different global regions .....................................................................132
Location of Phase I unit(s) within your country ...............................................................................132
Low cost ...........................................................................................................................................133
Meeting database lock timelines .....................................................................................................133
Meeting first patient / first visit timelines .......................................................................................134
Meeting overall project timelines ....................................................................................................134
Minimizing change orders ................................................................................................................135
Minimizing staff turnover ................................................................................................................135
Offered innovative solutions ...........................................................................................................136
Patient / volunteer recruitment ......................................................................................................136
Project manager quality ..................................................................................................................137
Project team chemistry ...................................................................................................................137
Responsiveness ................................................................................................................................138
Scientific knowledge ........................................................................................................................138
Speed of site start-up .......................................................................................................................139
Technology for real-time access to data ..........................................................................................139
Therapeutic expertise ......................................................................................................................140
Timely access to open bed / clinic space .........................................................................................140
Timely project communications ......................................................................................................141
Up-front contingency planning, risk management ..........................................................................141
Sponsor Preferences ............................................................................................................................142
Scenario Trade-offs ..........................................................................................................................142
Service Provider Input Usefulness .......................................................................................................143
Respondent Demographics ..................................................................................................................144
Company Type ..................................................................................................................................144
Primary Area of Responsibility .........................................................................................................145
Outsourcing Responsibility ...............................................................................................................146
Job Title ............................................................................................................................................146
Recent Activity in Outsourced Activities .........................................................................................147
Phase Responsibility ........................................................................................................................147
Involvement in Clinical Development Process ................................................................................148
Years in the Industry ........................................................................................................................149
Location ...........................................................................................................................................149
Therapeutic Area .............................................................................................................................150
About Industry Standard Research ..........................................................................................................151